Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Stivarga (Regorafenib) for Treating Metastatic Colorectal Cancer (mCRC)

Drug (Brand / Generic)

Stivarga / regorafenib

Company / Licensee

Bayer HealthCare / Onyx Pharmaceuticals

Therapy Class

Multikinase inhibitor

Current Indication

Metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumours (GIST)

Market Sector

Oncology

Development Status

Approved in the US, Europe and Japan
Expand
Close
Close
Close

Go Top